Meridian In Alliance With Genpharm
Meridian Medical Technologies of the USA has formed a long-termstrategic alliance with Genpharm, a subsidiary of E Merck, which is part of Merck KGaA of Germany, for the marketing of "a major generic injectable drug."
The identity of the product is not revealed by the companies, but they say that it achieved turnover in 1996 of $100 million globally. Meridian will manufacture it and Genpharm will market it.
Under the terms of the agreement, Genpharm receives exclusive Canadian marketing rights to the product and also receives an option for exclusive marketing rights in Europe, Australia and New Zealand.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze